adalimumab

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
Marcin Stajszczyk, Izabela Obarska, Slawomir Jeka, Bogdan Batko

Annals of the Rheumatic Diseases Sep 2023, 82 (9) 1171-1180; DOI: 10.1136/ard-2022-223696
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis
Chuan Fu Yap, Nisha Nair, Annick de Vries, Floris C Loeff, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Anne Barton, Darren Plant

Annals of the Rheumatic Diseases Feb 2024, 83 (2) 263-265; DOI: 10.1136/ard-2023-223955
Time to treat the climate and nature crisis as one indivisible global health emergency
Chris Zielinski

Annals of the Rheumatic Diseases Dec 2023, 82 (12) 1506-1507; DOI: 10.1136/ard-2023-225126
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Lea Hoisnard, Laura Pina Vegas, Rosemay Dray-Spira, Alain Weill, Mahmoud Zureik, Emilie Sbidian

Annals of the Rheumatic Diseases Feb 2023, 82 (2) 182-188; DOI: 10.1136/ard-2022-222824
Thank you to our reviewers 2022
Annals of the Rheumatic Diseases Apr 2023, 82 (4) 583-584; DOI: 10.1136/ard-2023-223894
Neuroinflammatory events after anti-TNFα therapy
Evripidis Kaltsonoudis, Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos

Annals of the Rheumatic Diseases May 2022, 81 (5) e73; DOI: 10.1136/annrheumdis-2020-217723
Response to: Where are the women ‘Heroes and Pillars of Rheumatology’?
Josef S Smolen

Annals of the Rheumatic Diseases Aug 2023, 82 (8) e200; DOI: 10.1136/annrheumdis-2021-222050
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan

Annals of the Rheumatic Diseases Jul 2006, 65 (7) 889-894; DOI: 10.1136/ard.2005.043166
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley B Cohen, Ronald F van Vollenhoven, Kevin L Winthrop, Cristiano A F Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara Hendrickson, Jeffrey V Enejosa, Gerd R Burmester

Annals of the Rheumatic Diseases Mar 2021, 80 (3) 304-311; DOI: 10.1136/annrheumdis-2020-218510
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Roy M Fleischmann, Ricardo Blanco, Stephen Hall, Glen T D Thomson, Filip E Van den Bosch, Cristiano Zerbini, Louis Bessette, Jeffrey Enejosa, Yihan Li, Yanna Song, Ryan DeMasi, In-Ho Song

Annals of the Rheumatic Diseases Apr 2021, 80 (4) 432-439; DOI: 10.1136/annrheumdis-2020-218412

Main menu

adalimumab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

adalimumab

Pages